论文部分内容阅读
目的监测慢性乙肝(CHB)患者治疗前及治疗中血清HBsAg与HBeAg的浓度变化,评价其与治疗效果的关系。方法分析采用核苷类似物治疗48周的CHB患者HBs Ag、HBeAg基线及用药后24周HBsAg、HBeAg水平变化。结果 HBeAg阴性的CHB患者HBsAg基线中位数为13 228.86 COI,HBeAg阳性CHB患者用药后24周HBeAg水平中位数为237.82 COI,反弹组和持续应答组的差异均有统计学意义(P<0.05)。结论 HBeAg阴性的CHB患者的HBsAg基线及HBeAg阳性CHB患者治疗24周的HBeAg水平,对CHB核苷类似物的治疗效果有预测价值。
Objective To monitor the changes of serum HBsAg and HBeAg levels in patients with chronic hepatitis B (CHB) before and during treatment and evaluate their relationship with the therapeutic effect. Methods The HBsAg and HBeAg levels in CHB patients treated with nucleoside analogues for 48 weeks and HBsAg and HBeAg levels at 24 weeks after treatment were analyzed. Results The median HBsAg of HBeAg-negative CHB patients was 13 228.86 COI. The median HBeAg level of HBeAg-positive CHB patients after 24 weeks of treatment was 237.82 COI. The difference between the rebound group and the sustained response group was statistically significant (P <0.05 ). Conclusions HBeAg levels in HBeAg-negative CHB patients and HBeAg levels in 24-week HBeAg-positive CHB patients are predictive for the therapeutic efficacy of CHB nucleoside analogues.